PPBT
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Purple Biotech presented new data from the CAPTN-3 platform for tri-specific IM1240Apr 27, 2026
- Purple Biotech receives intention to grant a European patent covering NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor resistanceSep 10, 2025
- Purple Biotech announces new data supporting unique design of CAPTN-3 tri-specific antibody IM1240 in collaboration with Icahn School of Medicine at Mount SinaiSep 4, 2025
- Purple Biotech expands CAPTN-3 portfolio with IM1305, a novel tri-specific antibody targeting TROP2Sep 3, 2025
- Purple Biotech begins Phase 2 study of NT219 in patients with head and neck cancerJun 17, 2025